Stocks and Investing Stocks and Investing
Wed, November 16, 2022
Tue, November 15, 2022

Robyn Karnauskas Maintained (BIIB) at Strong Buy with Increased Target to $350 on, Nov 15th, 2022


Published on 2024-10-28 00:11:11 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $265 to $350 on, Nov 15th, 2022.

Robyn has made no other calls on BIIB in the last 4 months.



There are 22 other peers that have a rating on BIIB. Out of the 22 peers that are also analyzing BIIB, 6 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Yatin Suneja of "Guggenheim" Maintained at Hold with Increased Target to $270 on, Friday, November 11th, 2022
  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $220 on, Wednesday, October 26th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $275 on, Friday, October 7th, 2022
  • Chris Schott of "JP Morgan" Maintained at Hold with Increased Target to $275 on, Friday, September 30th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Increased Target to $280 on, Wednesday, September 28th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $217 on, Wednesday, September 28th, 2022


These are the ratings of the 16 analyists that currently disagree with Robyn


  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $315 on, Monday, November 14th, 2022
  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $325 on, Tuesday, November 1st, 2022
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $370 on, Wednesday, October 26th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $310 on, Wednesday, October 26th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $325 on, Wednesday, October 26th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $325 on, Wednesday, October 26th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $331 on, Wednesday, October 26th, 2022
  • Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $325 on, Monday, October 24th, 2022
  • Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Held Target at $299 on, Thursday, October 13th, 2022
  • Jasper Hellweg of "Argus Research" Upgraded from Hold to Strong Buy on, Friday, October 7th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $309 on, Thursday, October 6th, 2022
  • Brian Skorney of "Baird" Upgraded from Hold to Buy and Increased Target to $340 on, Wednesday, September 28th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $360 on, Wednesday, September 28th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $350 on, Wednesday, September 28th, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
Contributing Sources